Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the successful completion of a toxicology safety study of its lead MagSense® nanoparticle formulation for the detection of HER2 metastatic breast cancer.
Read the announcement.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer